SAMANTREE-MEDICAL
16.7.2024 07:01:34 CEST | Business Wire | Press release
SamanTree Medical, a leading medical technology company specializing in innovative solutions to improve the outcomes of surgery, today announced the closing of $14M as part of a Series B financing round. The new capital will be used to further develop and commercialize the Histolog® Scanner, expand its reach in Europe and the United States, and enhance its digital suite.
Revolutionizing Surgery with the Histolog® Scanner
The Histolog Scanner, a CE-marked device, allows for high-resolution imaging of fresh tissue surfaces during surgery, enabling pathologists and surgeons to perform real-time intra-operative assessment of resected tissue much faster than the conventional techniques. This innovative technology is based on ultra-fast confocal microscopy.
Investment
The round was led by Relyens Innovation Santé, advised by Turenne Capital, and saw participation from new investors Mutuelles Impact, Wille Finance, Noshaq and WE Life Sciences (Wallonie Entreprendre), along with returning investors Panakès Partners, BOM and b2venture. In conjunction with this financing round, SamanTree Medical will establish its headquarters and an operational base in Wallonia (Belgium), while the R&D operations will remain in Lausanne, Switzerland. Fraser Partners acted as sole financial advisor to SamanTree Medical SA.
Board of Directors Update
Joining the Board of Directors are Claire Poulard, Investment Director at Turenne Capital, and Henry Charlton, SVP and Chief Commercial & Marketing Officer at Intuitive. The new Board composition is as follows:
- Fabrizio Landi
- Claire Poulard
- Henry Charlton
- Dr. Charles Carignan (Chairman)
- Olivier Delporte (CEO)
CEO Olivier Delporte explained: “We are elated by the robust support from our investors, which highlights SamanTree Medical's impressive progress. This funding, coupled with our strengthened Board, will enable us to accelerate our innovation, expand globally, and enhance our digital solutions, thereby delivering greater value to patients. I also want to thank the Walloon investors WE Life Sciences and Noshaq for their continuing support and effort to strengthen the local life sciences ecosystem.”
“SamanTree Medical has demonstrated that the Histolog® Scanner can provide real-time, high-resolution imaging during surgery, and it has the potential to improve surgical outcomes. We are impressed with the company's performance and the clinical data supporting the use of the Histolog® Scanner in multiple soft-tissue surgical procedures. We look forward to partnering with SamanTree Medical to bring this transformative technology to more patients worldwide,” said Claire Poulard, Investment Director at Turenne Capital.
“I am excited to join the Board of SamanTree Medical at such a pivotal time for the company. The Histolog Scanner is a potentially significant advancement that provides surgeons with real-time actionable information to their decision-making,” said Henry Charlton, SVP and Chief Commercial Officer at Intuitive.
Strategic Vision and Global Expansion
As part of the financing conditions, SamanTree Medical is set to expand its commercial operations in Europe and is planning for US market entry later in 2024. This strategic move will involve scaling the deployment of the Histolog Scanner, bolstering clinical trials, and working to obtain necessary marketing authorizations from the U.S. FDA.
About SamanTree Medical and the Histolog Scanner
SamanTree Medical is dedicated to improving outcomes for patients undergoing surgery through innovative medical imaging solutions. The company has developed the Histolog Scanner, a novel device that offers real-time, high-resolution fresh tissue surface imaging during surgical procedures, that may significantly enhance the accuracy of tissue removal or biopsy. The Histolog Scanner covers a broad range of surgical applications in surgery and is currently commercialized in Europe. It is an investigational device in the US.
For more information, visit www.samantree.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240715376136/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom